Blenrep
What Blenrep is used for
Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Blenrep
- Active substance
- belantamab mafodotin
- Disease area
- Multiple Myeloma
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX15
- Marketing authorisation holder
- GlaxoSmithKline Trading Services Limited
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Blenrep
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Blenrep used for?
Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.
What is the active substance in Blenrep?
Blenrep contains belantamab mafodotin.
Who makes Blenrep?
The EU marketing authorisation holder is GlaxoSmithKline Trading Services Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU